This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Windler, E. Articles by Zyriax, B.-C. Search for Related Content PubMed PubMed Citation Articles by Windler, E. Articles by Zyriax, B.-C. Social Bookmarking                         What's this?

The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease

Center of Internal Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

Mark Schöffauer

Center of Internal Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

Birgit-Christiane Zyriax

Center of Internal Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

In most developed and developing countries, the proportion of the population aged 60 years or more is growing faster than any other age group. Given that the vast majority of cardiovascular events occur in older individuals, new thinking is needed to reduce their risk. Epidemiological studies have shown an increasing prevalence of the metabolic syndrome with age, driven by nutrition inappropriate for a modern sedentary lifestyle. A low level of high-density lipoprotein (HDL)-cholesterol, a component of the atherogenic dyslipidaemia of the metabolic syndrome, has been shown to be an important determinant of coronary risk, which rises in prevalence with increasing age. Thus, raising HDL-cholesterol, in addition to lowering the level of low-density lipoprotein (LDL)-cholesterol, seems a plausible approach to reduce cardiovascular risk in an ageing population.

Clinical studies have shown that adding nicotinic acid, which raises HDL-cholesterol by 20-25%, to a statin enhances the reduction in progression of atherosclerosis. Results of the ongoing Atherothrombosis Intervention in Metabolic syndrome with low HDL/High triglyceride and Impact on Global Health Outcomes (AIM-HIGH) study are awaited with interest to see whether such theoretical benefit translates into clinical outcome.

Key Words: cardiovascular disease • combination therapy • coronary heart disease • fibrate • HDL-cholesterol • lipid-lowering therapy • metabolic syndrome • nicotinic acid • statin

Diabetes and Vascular Disease Research, Vol. 4, No. 2, 136-142 (2007)
DOI: 10.3132/dvdr.2007.032


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Eldor and I. Raz American Diabetes Association Indications for Statins in Diabetes: Is there evidence? Diabetes Care, November 1, 2009; 32(suppl_2): S384 - S391. [Full Text] [PDF]

				J. W.A. van der Hoorn, W. de Haan, J. F.P. Berbee, L. M. Havekes, J. W. Jukema, P. C.N. Rensen, and H. M.G. Princen Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 2016 - 2022. [Abstract] [Full Text] [PDF]